
Annual report 2025
added 03-04-2026
OrthoPediatrics Corp. Revenue 2011-2026 | KIDS
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue OrthoPediatrics Corp.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 236 M | 205 M | 149 M | 122 M | 98 M | 71.1 M | 72.6 M | 57.6 M | 45.6 M | 37.3 M | 31 M | 23.7 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 236 M | 23.7 M | 95.7 M |
Quarterly Revenue OrthoPediatrics Corp.
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 61.1 M | 52.4 M | 54.6 M | 52.8 M | 44.7 M | 40 M | 39.6 M | 31.6 M | - | 35 M | 32.9 M | 23.4 M | 24.8 M | 25.1 M | 26.7 M | 21.5 M | 18.9 M | 22.2 M | 13.6 M | 16.4 M | 19 M | 20.7 M | 18.2 M | 14.7 M | 14.6 M | 15.8 M | 15.1 M | 12.1 M | 11.7 M | 12.4 M | 11.8 M | 9.76 M | 9.42 M | 10.1 M | 9.67 M | 8.07 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 61.1 M | 8.07 M | 24.3 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Globus Medical
GMED
|
2.94 B | $ 90.0 | 1.58 % | $ 12.2 B | ||
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
7.16 M | - | -26.83 % | $ 2.62 M | ||
|
AdaptHealth Corp.
AHCO
|
3.24 B | $ 11.94 | -1.08 % | $ 1.61 B | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
Helius Medical Technologies
HSDT
|
644 K | $ 1.83 | -3.68 % | $ 1.11 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
1.61 B | $ 9.33 | 0.21 % | $ 719 M | ||
|
ClearPoint Neuro
CLPT
|
37 M | $ 9.07 | -3.3 % | $ 257 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
Bruker Corporation
BRKR
|
3.37 B | $ 36.67 | -0.19 % | $ 5.46 K | ||
|
IRIDEX Corporation
IRIX
|
52.7 M | $ 1.03 | 3.35 % | $ 17.4 M | ||
|
Integer Holdings Corporation
ITGR
|
1.85 B | $ 85.11 | -0.61 % | $ 2.96 B | ||
|
LENSAR
LNSR
|
58.4 M | $ 5.63 | -4.41 % | $ 67.3 M | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
Medtronic PLC
MDT
|
33.5 B | $ 86.42 | 0.15 % | $ 111 B | ||
|
FONAR Corporation
FONR
|
97.6 M | $ 18.58 | -0.11 % | $ 122 M | ||
|
Myomo
MYO
|
40.9 M | $ 0.68 | -3.62 % | $ 28.5 M | ||
|
EDAP TMS S.A.
EDAP
|
44.1 M | $ 3.4 | -1.73 % | $ 127 M | ||
|
Orthofix Medical
OFIX
|
822 M | $ 11.71 | -0.51 % | $ 464 M | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | ||
|
Align Technology
ALGN
|
4 B | $ 166.87 | -2.91 % | $ 12.5 B | ||
|
AxoGen
AXGN
|
225 M | $ 30.99 | -5.06 % | $ 1.43 B | ||
|
Insulet Corporation
PODD
|
2.71 B | $ 202.46 | -0.51 % | $ 14.2 B | ||
|
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
12.3 M | - | 1.37 % | $ 20.5 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
Sintx Technologies
SINT
|
1.02 M | $ 2.66 | 5.14 % | $ 7.38 M | ||
|
Smith & Nephew plc
SNN
|
4.56 B | $ 31.73 | -2.74 % | $ 23.8 B | ||
|
Stryker Corporation
SYK
|
7.17 B | $ 332.07 | -0.1 % | $ 127 B | ||
|
Tactile Systems Technology
TCMD
|
330 M | $ 24.05 | -2.12 % | $ 550 M | ||
|
Butterfly Network
BFLY
|
82.1 M | $ 4.05 | -1.94 % | $ 857 M | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
Tandem Diabetes Care
TNDM
|
290 M | $ 18.28 | -4.64 % | $ 1.24 B | ||
|
Cytosorbents Corporation
CTSO
|
37.1 M | $ 0.61 | 3.37 % | $ 38 M | ||
|
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | ||
|
Delcath Systems
DCTH
|
85.2 M | $ 9.67 | -0.31 % | $ 346 M | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
20.1 B | $ 61.86 | -1.17 % | $ 91.6 B | ||
|
Alphatec Holdings
ATEC
|
764 M | $ 11.03 | 0.55 % | $ 1.66 B | ||
|
Varex Imaging Corporation
VREX
|
845 M | $ 10.59 | 0.28 % | $ 438 M | ||
|
CONMED Corporation
CNMD
|
1.37 B | $ 34.54 | 1.35 % | $ 1.07 B | ||
|
Beyond Air
XAIR
|
3.7 M | $ 0.71 | 0.14 % | $ 48.1 M |